Rankings
▼
Calendar
SAVA
Cassava Sciences, Inc.
$116M
Q4 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
-$19M
Operating Income
-$23M
Net Income
-$21M
EPS (Diluted)
$-0.50
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$22M
Free Cash Flow
-$22M
Stock-Based Comp.
$2M
Balance Sheet
Total Assets
$152M
Total Liabilities
$14M
Stockholders' Equity
$137M
Cash & Equivalents
$121M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
-$19M
-$18M
-6.1%
Operating Income
-$23M
-$21M
-8.8%
Net Income
-$21M
-$19M
-9.3%
← FY 2023
All Quarters
Q1 2024 →
SAVA Q4 2023 Earnings — Cassava Sciences, Inc. Revenue & Financial Results | Market Cap Arena